Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 0.72 |
| ▸ | PDE4C | Q08493 | 16/20 | 0.72 |
| ▸ | PDE4A | P27815 | 10/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.72 |
| ▸ | HTR2B | P41595 | 1/20 | 0.65 |
| ▸ | TNF | P01375 | 5/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537226 | 0.94 | PDE4B (0.76) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537225 | 0.94 | PDE4B (0.76) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537144 | 0.93 | PDE4B (0.72) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL23000598 | 0.92 | PDE4B (0.73) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537359 | 0.92 | PDE4B (0.70) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537248 | 0.92 | PDE4B (0.70) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL30568351 | 0.91 | PDE4B (0.87) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL21494501 | 0.91 | PDE4B (0.87) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL30568353 | 0.91 | PDE4B (0.87) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL21494453 | 0.90 | PDE4B (0.70) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767295-B2 | Isoindole derivative | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2023-09-26 | — | — | US | claimed |
| US-20210155590-A1 | ISOINDOLE DERIVATIVE | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2021-05-27 | — | — | US | claimed |
| US-11767295-B2 | Isoindole derivative | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2023-09-26 | — | — | US | disclosed |
| US-20210155590-A1 | ISOINDOLE DERIVATIVE | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2021-05-27 | — | — | US | disclosed |
| WO-2019201255-A1 | ISOINDOLE DERIVATIVE | 天津合美医药科技有限公司 | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767295-B2 | Isoindole derivative | COX4I1, ALDH1A2, GDI2 | PDE4B 1378/4885PDE4C 2317/4885PDE4A 1740/4885 |
| US-20210155590-A1 | ISOINDOLE DERIVATIVE | COX4I1, ALDH1A2, GDI2 | PDE4B 1378/4885PDE4C 2317/4885PDE4A 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.